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Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-
small-cell lung cancer (NSCLC). The role of older agents was underattended over the last years. This study presents the combination
of Mitomycin C and Vinorelbine in pretreated patients. Forty-two patients (stage IIIB and IV, pretreated with platinum-based
chemotherapy) received 8mgm
2 Mitomycin C on day 1 and 25mgm
2 Vinorelbine on days 1 and 8 of a 28-day cycle. End points
were objective tumour response, survival, and toxicity. Additionally, quality of life (QoL) was assessed. Five patients (11.9 %) achieved
partial responses and 13 patients (31.9%) stable disease. Progression-free survival was 16 weeks. The median overall survival was 8.5
month. Eleven patients (26.2 %) suffered from grade 3 or 4 neutropenia and four patients (9.52%) from grade 3 or 4 anaemia.
Evaluation of QoL showed that some items ameliorated during therapy. The therapeutic concept including Mitomycin C and
Vinorelbine offers an efficacious and well-tolerated regimen, with relatively low toxicity. Objective response and survival data
correlate with other second-line studies using different medication. As costs of Mitomycin C and Vinorelbine are lower compared
with current drugs of choice, this regimen is likely to be cost-saving.
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Lung cancer is the most common cancer in the world today (12.3%
of all new cases), with an estimated 1.2 million new cases and 1.1
million deaths (17.8% of all cancer deaths) worldwide in 2000.
Non-small-cell lung cancer accounts for approximately 80% of all
cases of lung cancer (Landis et al, 1998). For chemotherapy-naive
patients with a good performance status (PS) and stage IIIb or IV
disease, platinum-based chemotherapy offers a modest survival
advantage over best supportive care (BSC) alone (Grilli et al, 1993;
Non-small Cell Lung Cancer Collaborative Group, 1995). Docetaxel
was the first of the US Food and Drug Administration and
European Agency for the Evaluation of Medical Products-approved
chemotherapy agent for the second-line treatment of advanced
NSCLC. The approval was based on two phase III studies (Fossella
et al, 2000a; Shepherd et al, 2000). For patients with a good PS at
the time of disease progression following first-line chemotherapy,
docetaxel, despite a low response rate, is associated with a 10–20%
increase of 1-year survival and an improved quality of life when
compared with ifosfamide, Vinorelbine, or BSC alone. In 2004 and
2005, the two new substances Pemetrexed and Erlotinib received
Food and Drug Administration approval for the second-line
treatment of locally advanced or metastatic NSCLC. The median
survival time ranges between 6.7 and 8.3 months. In view of the
modest results of these drugs, other agents with single-agent
activity in NSCLC are greatly needed for this patient population.
An additional important factor is cost effectiveness that gains
increased attention among healthcare systems in many countries.
This phase II trial focused on the efficacy and tolerability of
Mitomycin C in combination with Vinorelbine in pretreated
patients suffering from NSCLC. The trial shows the application of a
regimen, which is established and frequently used for patients with
advanced breast cancer.
MATERIALS AND METHODS
Patient eligibility
This trial was conducted at our institution between January 2002
and April 2005. Eligible patients had locally advanced or metastatic
NSCLC that had progressed during or after prior chemotherapy
regimen. Before study entry, a minimum of 21 days must have
elapsed since any prior chemotherapy. Patients may have had
either measurable or assessable lesions. Eastern Cooperative
Oncology Group performance status of 0–2 was required, as was
adequate bone marrow (absolute granulocyte count of
X1.510
9cellsl
1 and platelet count of X10010
9cellsl
1),
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shepatic (total bilirubin level within normal limits, alkaline
phosphatase level p5 times the upper limit of normal, and serum
transaminase p1.5 times the upper limit of normal), and renal
(serum creatinine level p2.0mgdl
1 or creatinine clearance
p60mlmin
1) function. No restriction was placed on the number
of prior chemotherapy regimens or the amount of prior
chemotherapy. Patients with prior Mitomycin C or Vinorelbine
treatment were not included. Patients who had received prior
radiation therapy were eligible provided that at least 30 days had
elapsed from the completion of radiation to study entry. Patients
with treated brain metastases were eligible provided that they
were neurologically stable. All patients provided written informed
consent. The study was approved by local institutional review
boards and was conducted in compliance with institutional review
board regulations.
Treatment plan
Eligible patients were assigned to receive the combination of
Mitomycin C and Vinorelbine. Patients were stratified according
to stage of disease (stage IIIB or IV) and performance status (0 or
1 vs 2).
Patients received 8mgm
2 Mitomycin C as a 10-min intra-
venous infusion on day 1 and 25mgm
2 Vinorelbine as a 10-min
intravenous infusion on days 1 and 8 of a 28-day cycle.
Chemotherapy was given over six cycles or until disease
progression, unacceptable toxicity, or until the patient or the
investigator requested therapy discontinuation. Patients were
instructed to take dexamethasone (4mg orally twice daily the
day of, and the day after each chemotherapy infusion). Ondan-
strone was administered on the day of and the day after
chemotherapy infusion.
Haematopoietic growth factors were not used prophylactically
but were permitted therapeutically at the discretion of the treating
physician. Prophylactic antiemetics were permitted.
The baseline assessment included a history and physical
examination, complete blood count, comprehensive blood
chemistries, calculated creatinine clearance, and computed tomo-
graphy scan of the chest. Bone scans and brain imaging were
performed only if clinically indicated.
The Lung Cancer Symptom Scale (LCSS) was administered at
baseline and weekly during the study. The observer LCSS was
administered at baseline and at the end of each cycle. Toxicity
evaluations were based on the National Cancer Institute CTC,
version 2. Haematologic laboratory values were evaluated weekly.
Chemistry laboratory values were evaluated following days 1 and 8
of each cycle. Tumour measurements were assessed after every two
cycles.
Evaluation of response
Tumour responses were assessed radiographically every two
cycles. Designations of complete response, partial response, no
change, and progressive disease were based on the standardised
response definitions established by the World Health Organiza-
tion. Duration of response and time to progression were calculated
as time from enrollement to the first objective evidence of tumour
progression. Survival was calculated from the date of recruiting
until death. Patients were treated for a minimum of two cycles
(unless this was precluded by unacceptable toxicity or rapid
disease progression). Patients with response or stable disease
continued treatment for at least six cycles unless there was disease
progression or unacceptable side effects. Patients who were
responding or had stable disease could receive more than six
cycles if they were achieving continued clinical benefit as
determined by the treating physician. Patients with disease
progression, unacceptable toxicity, treatment delay of more than
3 weeks, or intercurrent conditions that precluded continued
treatment were removed from the study. On removal from study,
patients were to be observed every 2 months until death to assess
adverse events, quality of life, disease status, and survival.
QOL assessment
QoL assessment was scheduled to be carried out at baseline and
after drug treatment end. The validated instrument was the EORTC
QLQ-C30 instrument with the LC 13 lung cancer module.
The instrument consists of a core questionnaire incorporating a
global health and QoL scale, five multiitem function scales
(physical, role, cognitive, emotional, and social), three multiitem
symptom scales (fatigue, pain, nausea, and vomiting), and six
single-item symptom measures (dyspnea, insomnia, appetite loss,
constipation, diarrhea, and financial difficulties).
For each item, a linear transformation is applied to standardise
the raw score to a range from 0 to 100, with 100 representing the
best possible function/QoL, and highest burden of symptoms. All
30 items are rated by the patient.
Statistical analysis
The primary objective of the study was to evaluate response rate,
median survival, and time to progression. Secondary objectives
were toxicities (including use of concomitant supportive mea-
sures), time to progressive disease (TPD), time to treatment failure
(TTF), time to response, duration of response, and quality-of-life
measurements (using the LCSS).
The number of patients needed in this trial was determined
according to the optimal two-stage design for phase II studies
proposed by Simon et al. (1989).
The null hypothesis that the remission rate is 5% was tested
against the alternative hypothesis that the remission rate is at
least 20%. If the null hypothesis is true, then the probability of
erroneously concluding that the therapy is sufficiently promising
(type I error) was limited to 5%. If the alternative hypothesis is
true, the probability of erroneously rejecting the therapy for
further study (type II error) should be less than 20%.
With these constraints, the maximum required sample size was
37 evaluable patients. The first stage consisted of 17 patients. If the
number of responses after completing the first stage is 0, the trial
could be terminated owing to futility.
Statistical analyses were performed by the independent institute
GEM (Gesellschaft fu ¨r Evaluation und Qualita ¨tssicherung in der
Medizin, Meerbusch, Germany) using the statistical packages SAS
(SAS Institute, Cary, NC, USA), version 8.
RESULTS
Patient characteristics
A total of 42 patients were enrolled into the study. Median age was
63.9 (50–76) years. Seventeen per cent of the recruited patients
had stage IIIB disease and 83% of the patients had stage IV disease.
Demography is given in Table 1. All enrolled patients were
assessable for objective response and survival analyses. All patients
received treatment after inclusion into the study. Patients had
performance status of 0 or 1 despite their extensive prior therapy.
Treatment administration
Eighteen patients (43 %) received six cycles of chemotherapy and
completed the whole course. Two patients (4.7%) and 16 patients
(38.1%) were withdrawn from the study after one, respectively, and
two cycles of chemotherapy owing to toxicity or progression. At a
patient’s request, therapy with Mitomycin C and Vinorelbine could
be continued for further cycles out of the study.
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Objective response was assessed in 42 patients with histologically
confirmed NSCLC, who received at least two chemotherapy
infusions after inclusion. Partial response was observed in five
patients (11.9%). In those patients, PR was observed after two
cycles. After completion of six cycles, 13 patients (31.9%) were still
in stable disease. Progression-free survival was 16 weeks (CI 95%
2.6–31.1 weeks). Median survival was 8.5 month (CI 95% 4.2–12.8
months).
Safety and toxicity
Toxicity could be assessed in all 42 patients. Two patients were
reported to have neither haematological nor non-haematological
toxicity. Eleven patients (26.2%) had grade 4 neutropenia and
four patients (9.5%) suffered from grade 3 or 4 anaemia. Grade 3
or 4 nausea or vomiting occurred in four patients (9.5%). Five
patients (11.9%) received RBC transfusions (p2) among them
only one (2.4%) required transfusion because of therapy. One
patient obtained platelet transfusion. Filgrastim had not to be
administered.
Quality of life
A total of 30 patients (71.4%) completed the QLQ-C 30
questionnaire at the beginning of treatment, 25 patients (59.5%)
answered the questionnaire additionally at drug treatment end. For
patients who missed to complete the final questionnaire, the score
was evaluated as last score carried forward. Global healthcare
decreased from baseline 49.4 to last assessment value 40.8
(17.4%). The mean score for nausea, insomnia, and constipation
ameliorated during therapy.
DISCUSSION
Survival benefits in patients with advanced NSCLC with the
administration of platinum-based chemotherapy are modest in
general compared with BSC (Fossella, 2000a,b). Virtually all
patients with advanced disease, however, ultimately develop
disease progression after first-line therapy, and many such patients
who maintain a good performance status are offered the option of
second-line treatment (Lara et al, 2002). Many trials of second-line
chemotherapy for NSCLC have been conducted to assess the
efficacy of such therapy in second-line treatment. The most
promising data were shown for chemotherapy with docetaxel and
Pemetrexed (Hanna et al, 2004). Those drugs showed consistently
good survival data in pretreated patients and represent the
treatment of choice in second-line setting (Fossella et al, 1995,
2000b). Over the last years, also newly developed drugs such as
EGFR or VEGFR blocking agents were introduced for second-line
treatment.
The combination of Mitomycin C and Vinorelbine was studied
extensively in patients suffering from breast cancer (Agostara et al,
1994; Vici et al, 1996). Several studies for second-line treatment
were conducted in the past. Most studies used doses and intervals
as we used here. Doses of up to 10mgm
2 Mitomycin C were
tested there. The idea of implementing Mitomycin C in the
treatment of NSCLC has been generated as early as 1985 (Shinkai
et al, 1985; Beck et al, 1987; Botto et al, 1989). In those times,
treatment of NSCLC using chemotherapy was new and still
diversely discussed (Non-small Cell Lung Cancer Collaborative
Group, 1995). By then Mitomycin C was combined with either
platinum-containing drugs or vinca-alcaloids. Several small studies
elucidated the doublet combination of Mitomycin C and vinca-
alcaloids as shown in Table 2.
Comparing earlier data and data from the present study allow
several careful statements. All trials – including the present as
well – investigated relatively small groups of patients. Also the
treatment regimens varied slightly from the form applied today
only one trial focused on second-line treatment (Kris et al, 1985).
Data that could be generated with those former trials correlate with
today’s rates in many ways.
Table 1 Patients characteristics
Characteristic (%)
Sex
Male 83.3
Female 16.67
Age (years)
Median 64
Range 42–76
Performance status
0o r1 9 5
2
Prior platinum 100
Prior taxane 14.3
Best response, any prior chemotherapy
CR/PR 14.3
SD 33.3
PD/unknown 50/2.4
Time since last chemotherapy
o3month 71.4
Histology
Adenocarcinoma 50
Squamous cell carcinoma 40.47
Prior radiation 11.9
CR, complete remission; PD, progressive disease; PR, partial response; SD, stable
disease.
Table 2 Mitomycin in combination with vinorelbine, vindesine, or vinblastine in NSCLC
Author date
Chemotherapy
line Dose
Evaluable
patients
OR
(%)
Median
survival (weeks)
Our study Second Mito 8mgm
2 d1 q4w Vino 25mgm
2 d1, 8 q4w 42 11.9 37
Gralla et al (1994) First Mito 8mgm
2 d1 q4w Vino esc. 25–35mgm
2 (phase I) 42 34 43.5
Milleron et al (1991) First Mito 6mgm
2 d1 q3w Vino 25mgm
2 d1, 8, 15 q3w 21 23.8 —
Gatzemeier et al (1991a) First Mito 10mgm
2 d1 q4w Vind 3mgm
2 d1, 8 q4w 66 22.7 23
Gatzemeier et al (1991b) First Mito 10mgm
2 d1 Vind 3mgm
2 d1, d8 (max. 5mg) 58 22.4 27.7
Luedke et al (1990) First Induction: Vind/Mito then Mito 15mgm
2 d1 q6w Vind 3mgm
2 d1, 15, 29 q6w 122 27 20.4
Shinkai et al (1985) First Induction: Vind/Mito then Mito 8mgm
2 d1 q3w Vind 3mgm
2 d1 q2w 30 10 44.3
Kris et al (1985) First Induction: Vind/Mito then Mito 10mgm
2 d1 q6 to 8w Vind 3mgm
2 q2w 55 36 26.5
Kris et al (1985) Second Induction: Vind/Mito then Mito 10mgm
2 d1 q6 to 8w Vind 3mgm
2 q2w 29 17 21.3
Ruckdeschel et al (1984) First Mito 10mgm
2 d1 q3w Vinb 6mgm
2 d1 q3w 101 13 18
OR, overall response; Mito, mitomycin; Vinb, vinblastine; Vind, vindesine; Vino, vinorelbine.
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handled carefully because of small trial size – all trials showed
data, that compete with today’s second-line regimens. Toxicity is
limited to haematologic toxicity in several cases; however, the
chemotherapy is tolerated well, showing a low incidence of
patients disabling toxicities such as nausea, emesis, alopecia and
fatigue. Those data can also be compared with data from breast
cancer studies, which show similar rates of toxicity.
Tolerability of this regimen should be focused also in terms of
dose intensity. Milleron et al (1991) could show a median number
of 10 chemotherapy cycles given per patient. This could be proven
in the present trial, in which over 40% of the patients completed all
six planned cycles of treatment. Toxicity was also comparable to
today’s data with grade 3/4 anaemia of 8.3% and leucopenia of
33.3%.
Treatment over six cycles was shown to be possible and was
performed in some patients out of the study protocol. A known
side-effect of Mitomycin C is the haemolytic uremic syndrome
(HUS). One patient suffered from HUS after given 10 cycles of the
combination, but recovered completely. Haemolytic uremic
syndrome is thought to occur at a cumulative dose of X60mgm
2
of Mitomycin C; however, the relation between dose and
occurrence could not be shown persistently in the literature. Early
detection of HUS by screening for hemolysis and schistocytosis
might be helpful.
QoL assessment was also implemented into this study. Without
control group conclusions could only drawn from a comparison to
historic data focusing also onto second-line treatment. An earlier
trial comparing Docetaxel vs BSC showed that treatment gave a
moderate decrease for several items (pain: 12%, physical
function: 19%, global health status: 21%) (Dancey et al,
2004). In our study, the decrease was comparable with the items
physical function: 9.3% and global health status: 17.4%) The
item pain was difficult to compare because of different baseline
scores. Thus Dancey reported a decrease from baseline score 80–
68, whereas in our study the very low baseline of 30 moderately
increased to 36.7. The difference is possibly due to different
strategies of pain management that lead to incomparable values.
Compared with already published data, our results also under-
line the good tolerability of the combination therapy. Taking those
data into account, this regimen fulfils requirements of a modern
second-line treatment in terms of objective tumour response,
survival and quality of life benefit.
Being one of the most frequently diagnosed cancers, NSCLC
causes an enormous economic burden for healthcare systems
worldwide. As in many patients NSCLC is only eligible for
palliative chemotherapy treatment, drug costs are a major driver of
treatment costs in Europe. Therefore, it should be pointed out that
the costs of Mitomycin C and Vinorelbine are considerably lower
than those of the more recently developed drugs of choice for
second-line treatment. Based on German pharmacy prices (Rote
Liste 2006), the costs per cycle of Mitomycin C (8mgm
2) and
Vinorelbine (225mgm
2) are 574 EUR compared with 1802
EUR for Docetaxel (25mgm
2) and 3641 EUR for Pemetrexed
(500mgm
2), assuming a body surface of 1.8m
2; oral Erlotinib
(150mgday
1) costs 2590 EUR per month. Thus, within six cycles,
more than 18000 EUR could be saved by using Mitomycin C/
Vinorelbine instead of Pemetrexed. Although cost-effectiveness is
not only the motivation to choose a specific kind of therapy, it will
have to be considered increasingly when setting priorities in
collectively financed health care systems.
In times of targeted therapy, mitomycin might become of
particular interest in the future. It was shown recently that bclxl
and Bcl-2 modulate the chemosensitivity against various drugs
such as mitomycin. Influencing the activity of these genes, for
example using antisense oligunucleotides, could already show
experimentally to enhance the cytostatic effects of mitomycin (Emi
et al, 2005). It has been also documented that the presence of
Fanconi anemia/BRCA2 mutations in pancreatic cells is predictive
for sensitivity to Mitomycin, which causes DNA–interstrand
crosslinking (van der Heijden et al, 2005). Those mutations could
also be found in NSCLC patients and might be influencing
sensitivity to mitomycin therapy (Marsit et al, 2004).
Treatment using Mitomycin C and Vinorelbine for pretreated
patients with metastatic or locally advanced NSCLC was intro-
duced already almost 20 years ago, but was not used widely
over the last years. Data show promising efficacy data, toxicity
is modest and treatment costs are low. Nowadays it is difficult
to develop new treatment strategies or to change existing ones.
The currents guidelines are based on fairly large trials and
show acceptable results. Using older regimens should be followed
anyway. One cohort of patients which is still not treated with
full satisfaction is the group of older patients or people with
reduced PS or significant comorbidity. Those patients – and to a
lesser extend all treated patients – should be allowed to receive
well-tolerable cytostatic therapy. The recent introduction of
Pemetrexed and the use of small molecules for second-line
treatment are yielding for that direction. Most of the newly
launched trials try to focus on QoL issues and raise the concept of
symptom free plus progression free survival. Owing to its excellent
tolerability, the combination of Mitomycin C and Vinorelbine
might have its destination in patients with reduced PS of two or
lower.
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